Skip to main content
. 2011 Jun 26;130(1):3–14. doi: 10.1007/s00439-011-1028-3

Table 1.

Examples of genetic and genomic testing in personalized medicine

Pre-symptomatic risk assessment
 BRCA1/2 testing for breast cancera
 Lynch syndrome testing for hereditary colon cancerb
 Long QT intervalc,d
 Spinal Muscular Atrophye
Diagnosis
 Beta thalassemiaf
 Fusion genes and rearrangements including BCR-ABL, E2A-PBX1, TEL-AML1, and MLL in pediatric leukemiag
 Gene expression profiles define subtypes of breast cancerh
 Human Papilloma Virus detectioni
 Hepatitis C detectionj
 PCR detection of micro-organisms (bacteria, fungi)k
Prognosis
 Fragile X syndrome (number of trinucleotide repeats predicts severity)l
 Gene expression signatures and prognosis in breast cancerm
 Gene expression analysis and lymphoma prognosisn
Treatment and pharmacogenomics
 Therapies for targeted gene mutations in cancero
  EGFR point mutations in lung cancer and glioblastoma and cetuximab, gefitinib, erlotinib, panitumumab, lapatinib treatment
  KIT, PDGFR mutations in sarcoma, glioma, liver and renal cancer, melanoma and imatinib, nilotinib, sunitinib, sorafenib treatment
  BRAF mutations in melanoma treated by RAF inhibitors
  BCR-ABL translocation in chronic myelogenous leukemia treated by imatinib
  KRAS wild-type status correlated with resistance to EGFR inhibition
  PARP inhibitors in BRCA mutant breast, ovarian, prostate and pancreatic cancer
  Herceptin (Trastuzumab) in HER2 + breast cancer
 Pharmacogenomic applicationsp
  CYP 2C19*2 variant (rs4244285) associated with diminished clopidogrel responseq
  Rs2395029 testing for HLA-B*5701 allele, correlated with hypersensitivity to abacavir treatment for HIV+ patientsr

aRobson and Offit (2007), b EGAPP (2009a), Napolitano et al. (2005), Lehnart et al. (2007), e Prior et al. (2008), f Galanello and Origa (2010), Carroll et al. (2003), h Sorlie et al. (2001), i Nicol et al. (2010), Pham et al. (2010), k Tsalik et al. (2010), l Sherman et al. (2005), Kim and Paik (2010), Rosenwald et al. (2002), Macconaill and Garraway (2010), U.S. Food and Drug Administration (2011), Shuldiner et al. (2009), Colombo et al. (2008)